TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8600093

Group type: EXPERIMENTAL
Intervention: Interstitial Thermoradiotherapy (ITRT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Interstitial Radiotherapy (IRT)
Number of subjects: 173
Study: 1876365

Group type: EXPERIMENTAL
Intervention: Doppler group (preliminary assessment by umbilical artery resistance estimation)
Number of subjects: 897

Group type: COMPARATOR
Intervention: FHR group (preliminary assessment by computerized fetal heart rate analysis)
Number of subjects: 897
Study: 7102442

Group type: EXPERIMENTAL
Intervention: Control over social evaluation (ability to critique the evaluation and evaluate their evaluator)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Threatened group without control
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonthreatened group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Evaluated group (received bogus evaluations)
Number of subjects: 60
Study: 31984593

Group type: EXPERIMENTAL
Intervention: Foraminal enlargement (Group FE)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No foraminal enlargement (Group NFE)
Number of subjects: 22
Study: 30378288

Group type: EXPERIMENTAL
Intervention: Levosimendan infusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28388244

Group type: EXPERIMENTAL
Intervention: Daratumumab, elotuzumab, carfilzomib, ixazomib, panobinostat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drugs in patients with relapsed and/or refractory MM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel anti-MM drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapies in the management of patients with newly diagnosed MM
Number of subjects: 0
Study: 26691333

Group type: EXPERIMENTAL
Intervention: OM/AML/HCTZ 20/5/12.5
Number of subjects: 341

Group type: COMPARATOR
Intervention: OM/HCTZ 20/12.5
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: OM/AML/HCTZ 40/5/12.5
Number of subjects: 341
Study: 24402285

Group type: EXPERIMENTAL
Intervention: 4-hexyl-1,3-phenylenediol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 22249393

Group type: EXPERIMENTAL
Intervention: Coffee enema (3 times weekly for 6 visits)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral coffee consumption (2 times daily for 11 days)
Number of subjects: 11
Study: 20305034

Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (OC)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone-analogues (GnRH-a)
Number of subjects: 23
Study: 17991642

Group type: EXPERIMENTAL
Intervention: LCP group (fed formula with LCPs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: no-LCP group (fed formula without LCPs)
Number of subjects: 22
Study: 15663548

Group type: EXPERIMENTAL
Intervention: 22-oxacalcitriol (OCT) 5 microg, 10 microg, or 15 microg administered at the end of every HD for 12 weeks
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pooled OCT groups
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: High dose OCT groups
Number of subjects: 203
Study: 12490683

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 239

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 239
Study: 9864806

Group type: EXPERIMENTAL
Intervention: Polyoxidonium
Number of subjects: 56
Study: 7895356

Group type: EXPERIMENTAL
Intervention: Acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 micrograms/100 mL per minute)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1, 2, and 4 micrograms/100 mL per minute)
Number of subjects: 110
Study: 1914396

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) insufflation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 200
Study: 6947984

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine digluconate (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 600 ml placebo (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 600 ml 0.05% chlorhexidine digluconate (Group E)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 600 ml 0.05% chlorhexidine digluconate (Group D)
Number of subjects: 40
Study: 31039250

Group type: EXPERIMENTAL
Intervention: Family-based (FB) intervention
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Parent-only (PO) intervention
Number of subjects: 249

Group type: COMPARATOR
Intervention: Health education condition (HEC)
Number of subjects: 249
Study: 28693921

Group type: EXPERIMENTAL
Intervention: Couple based coping intervention (CBCI)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Individual coping intervention (ICI)
Number of subjects: 132
Study: 26449252

Group type: EXPERIMENTAL
Intervention: anti-H.pylori treatment
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: anti-H.pylori followed by celecoxib treatment
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 919
Study: 23588574

Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopy (MRS)
Number of subjects: 32
Study: 21328087

Group type: EXPERIMENTAL
Intervention: AS100‐1 antigens
Number of subjects: 508
Study: 19152130

Group type: EXPERIMENTAL
Intervention: RegEx (regadenoson with low-level exercise)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PlcEx (placebo with low-level exercise)
Number of subjects: 60

Group type: COMPARATOR
Intervention: AdenoSup (standard adenosine-supine protocol)
Number of subjects: 60
Study: 18181512

Group type: EXPERIMENTAL
Intervention: Miniaturized extracorporeal circulation (MECC System)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (ECC)
Number of subjects: 0
Study: 15162156

Group type: EXPERIMENTAL
Intervention: Pain management (analgesic treatment)
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) assessment using EORTC QLQ‐C30 and LC‐13
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Pain Management Index (PMI) evaluation
Number of subjects: 1021
Study: 11252622

Group type: EXPERIMENTAL
Intervention: Multiple surrogate endpoints
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single biomarker as a surrogate
Number of subjects: 0
Study: 9514373

Group type: EXPERIMENTAL
Intervention: Palliative care approaches
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 146
Study: 7974754

Group type: EXPERIMENTAL
Intervention: 5 cm transverse incision
Number of subjects: 181

Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 181
Study: 2521988

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous sedation
Number of subjects: 50
Study: 334219

Group type: EXPERIMENTAL
Intervention: Nomifensine 75 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31070860

Group type: EXPERIMENTAL
Intervention: Dermagraft (cellular matrix device)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oasis (noncellular matrix device)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dermagraft
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oasis
Number of subjects: 56

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 56
Study: 27387372

Group type: EXPERIMENTAL
Intervention: Alert for AFib intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Attention control session
Number of subjects: 80
Study: 25894458

Group type: EXPERIMENTAL
Intervention: Post-reduction external rotation immobilization (9 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Post-reduction internal rotation immobilization (11 patients)
Number of subjects: 20
Study: 23221375

Group type: EXPERIMENTAL
Intervention: Educational intervention for supervisors
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Educational intervention for workplace champions
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Mixed group (supervisors and workplace champions)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 340
Study: 20646904

Group type: EXPERIMENTAL
Intervention: CPAP recruitment (continuous positive airway pressure of 35 cm H(2)O for 40 seconds
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pressure control recruitment maneuver (PCRM) (pressure control ventilation with positive-end expiratory pressure of 15 cm H(2)O and pressure control above positive end-expiratory pressure of 35 cm H(2)O for 2 minutes)
Number of subjects: 16
Study: 19616998

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate + Modafinil
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278

Group type: COMPARATOR
Intervention: Modafinil
Number of subjects: 278
Study: 17670803

Group type: EXPERIMENTAL
Intervention: Academic detailing (postal bulletin plus outreach visit)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Postal bulletin
Number of subjects: 98
Study: 15136961

Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 32

Group type: COMPARATOR
Intervention: Containment
Number of subjects: 32
Study: 11682283

Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: diphenhydramine (active control)
Number of subjects: 9
Study: 9440175

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral LASIK
Number of subjects: 254

Group type: COMPARATOR
Intervention: Sequential bilateral LASIK
Number of subjects: 254
Study: 7944444

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) < 30 mg/m2
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) >= 30 - < 40 mg/m2
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) >= 40 - < 50 mg/m2
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) >= 50 - < 60 mg/m2
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) >= 60 mg/m2
Number of subjects: 134
Study: 3608652

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal comparison boys
Number of subjects: 0
Study: 29307112

Group type: EXPERIMENTAL
Intervention: 200 μg/day of chromium for 8 weeks
Number of subjects: 40
Study: 27494260

Group type: EXPERIMENTAL
Intervention: H2 vaccine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Healive®
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Havrix®
Number of subjects: 4

Group type: COMPARATOR
Intervention: hepatitis B vaccine
Number of subjects: 4
Study: 25626016

Group type: EXPERIMENTAL
Intervention: Lewis negative subjects
Number of subjects: 223

Group type: COMPARATOR
Intervention: Le(a-b+) group
Number of subjects: 223
Study: 22544837

Group type: EXPERIMENTAL
Intervention: Community program targeting smoking cessation
Number of subjects: 388
Study: 20095912

Group type: EXPERIMENTAL
Intervention: Group 1: reduced energy, fat and sucrose
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group 2: reduced energy and fat only
Number of subjects: 126

Group type: COMPARATOR
Intervention: Group 3: control
Number of subjects: 126
Study: 18387162

Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol once weekly (Group 1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intravenous alfacalcidol twice weekly (Group 2)
Number of subjects: 21
Study: 16627223

Group type: EXPERIMENTAL
Intervention: ertapenem 1 g daily
Number of subjects: 370

Group type: COMPARATOR
Intervention: piperacillin/tazobactam 13.5 g daily in 3-4 divided doses
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: ertapenem
Number of subjects: 370

Group type: COMPARATOR
Intervention: piperacillin/tazobactam
Number of subjects: 370
Study: 12682719

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg bolus followed by 12 mg/kg/h continuous infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 100
Study: 11053065

Group type: EXPERIMENTAL
Intervention: Lumbar approach to the epidural space
Number of subjects: 200

Group type: COMPARATOR
Intervention: Caudal approach to the epidural space
Number of subjects: 200
Study: 8962902

Group type: EXPERIMENTAL
Intervention: Octreotide and conventional handling
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional handling
Number of subjects: 99
Study: 1433889

Group type: EXPERIMENTAL
Intervention: Imipenem (IPM) (1.0‐1.5 g/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Aztreonam (AZT) (4 g/day) + Lincomycin (LCM) (1,200‐2,400 mg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Imipenem (IPM)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Aztreonam (AZT) + Lincomycin (LCM)
Number of subjects: 95
Study: 4008815

Group type: EXPERIMENTAL
Intervention: lodoxamide tromethamine, 0.25 mg four times daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study: 30458187

Group type: EXPERIMENTAL
Intervention: EG110 (110% MAV)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: EG100 (100% MAV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: CG100 (Control Group 100% MAV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: CG110 (Control Group 110% MAV)
Number of subjects: 39
Study: 28982691

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1021
Study: 27112322

Group type: EXPERIMENTAL
Intervention: Experimental agents in the MIDAS trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm with standard therapy
Number of subjects: 0
Study: 24559813

Group type: EXPERIMENTAL
Intervention: Swedish massage with aromatic ginger oil (SMGO)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional Thai massage (TTM)
Number of subjects: 140
Study: 22519705

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy (LSH)
Number of subjects: 72
Study: 20875371

Group type: EXPERIMENTAL
Intervention: linagliptin 10 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pioglitazone 45 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: linagliptin and pioglitazone co-administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: linagliptin
Number of subjects: 20

Group type: COMPARATOR
Intervention: pioglitazone
Number of subjects: 20
Study: 18633049

Group type: EXPERIMENTAL
Intervention: Acupressure at the extra 1 point
Number of subjects: 22

Group type: COMPARATOR
Intervention: Acupressure at the sham point
Number of subjects: 22
Study: 16465537

Group type: EXPERIMENTAL
Intervention: TransFix (TF)
Number of subjects: 68

Group type: COMPARATOR
Intervention: bioscrew (BS)
Number of subjects: 68
Study: 14967867

Group type: EXPERIMENTAL
Intervention: Eucaloric diet providing 8 g of CHO/kg of body weight
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Eucaloric diet providing 5 g of CHO/kg of body weight
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Eucaloric diet providing 3 g of CHO/kg of body weight
Number of subjects: 11
Study: 10930106

Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m2 i.v. weekly
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Leucovorin 100 mg/m2 i.v. followed by 5-fluorouracil 370 mg/m2 i.v. days 1-5, q 28 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m2 i.v. only day 1 + leucovorin 100 mg/m2 i.v. followed by 5-fluorouracil 370 mg/m2 i.v. days 1-3, q 28 days
Number of subjects: 99
Study: 8721466

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: bupivacaine 0.25%
Number of subjects: 0
Study: 1464655

Group type: EXPERIMENTAL
Intervention: Testosterone Only group (200 mg testosterone enanthate weekly for 8 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Placebo/Testosterone group (placebo for first 4 weeks, then 200 mg testosterone enanthate weekly for next 4 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo group (placebo injections for first 4 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 6388401

Group type: EXPERIMENTAL
Intervention: Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study: 30704533

Group type: EXPERIMENTAL
Intervention: Self-regulation with Small Changes (SC)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Self-regulation with Large Changes (LC)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: All conditions (SC, LC, C)
Number of subjects: 599
Study: 28204882

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 50 µg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vaginal misoprostol 50 µg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both routes (sublingual and vaginal)
Number of subjects: 102
Study: 24528531

Group type: EXPERIMENTAL
Intervention: 25 mg bupivacaine plus 8 mg dexamethasone (active group)
Number of subjects: 138

Group type: COMPARATOR
Intervention: 10 mL saline (placebo group)
Number of subjects: 138
Study: 24620839

Group type: EXPERIMENTAL
Intervention: Quality assurance (QA) programme for the CONVERT trial
Number of subjects: 64
Study: 22564989

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/d plus erlotinib 150 mg/d
Number of subjects: 960

Group type: COMPARATOR
Intervention: Placebo plus erlotinib 150 mg/d
Number of subjects: 960
Study: 18330698

Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg on days 1 and 29) + Exemestane (25 mg once daily for 8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Triptorelin alone (3.75 mg on days 1 and 29)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Triptorelin + Exemestane
Number of subjects: 28
Study: 17336652

Group type: COMPARATOR
Intervention: artemether-lumefantrine
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 774
Study: 15104612

Group type: EXPERIMENTAL
Intervention: Interview-assisted questionnaire
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Self-completion questionnaire
Number of subjects: 114
Study: 11574775

Group type: EXPERIMENTAL
Intervention: Initial T(1-2)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: No initial nodal involvement
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: No initial chemotherapy exposure
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy response
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Duration of disease-free interval (DFI)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Performance status (PS) 0-1
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Local-regional recurrence
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Multivariate analysis excluding DFI
Number of subjects: 496
Study: 9448611

Group type: EXPERIMENTAL
Intervention: Enteral nutrition through a nasoenteric tube with a semi‐elemental diet (n = 18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Parenteral nutrition through a central venous catheter (n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 38
Study: 8073865

Group type: EXPERIMENTAL
Intervention: Nasal challenge with bradykinin (1 mg in 10% ethanol in 0.9% saline)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oropharyngeal challenge with bradykinin (1 mg in 10% ethanol in 0.9% saline)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control nasal challenge with ethanol/saline vehicle
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasal challenge with bradykinin
Number of subjects: 12
Study: 3034188

Group type: EXPERIMENTAL
Intervention: Gamma-vinyl gamma-aminobutyric acid (GVG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4,5,6,7-tetrahydroisoxazolo-(5,4-c)pyridine-3-ol (THIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondyskinetic controls
Number of subjects: 0
Study: 28744992

Group type: EXPERIMENTAL
Intervention: Carnosine 1 g/day for 12 weeks
Number of subjects: 90
Study: 28701161

Group type: EXPERIMENTAL
Intervention: Podiatry intervention (core podiatry care, foot and ankle exercises, orthoses, and footwear provision)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Podiatry intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Podiatry intervention and usual care
Number of subjects: 43
Study: 25845628

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 35
Study: 23040375

Group type: EXPERIMENTAL
Intervention: 5 Hz 'real' pharyngeal stimulation for 10 min (10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 'sham' pharyngeal stimulation for 10 min (10 patients)
Number of subjects: 20
Study: 20653477

Group type: EXPERIMENTAL
Intervention: NAC 5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Preservative-free artificial tears
Number of subjects: 20
Study: 19819096

Group type: EXPERIMENTAL
Intervention: Theory-based decision-making uncertainty management intervention (DMUMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16731135

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 120
Study: 12492740

Group type: EXPERIMENTAL
Intervention: rabeprazole (20 mg b.d.), amoxicillin (750 mg b.d.), metronidazole (250 mg b.d.) for 1 week
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: rabeprazole-amoxicillin-metronidazole
Number of subjects: 92
Study: 10594201

Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics plus syringe pressure irrigation of the surgical wound with 300 ml of saline solution.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Prophylactic systemic antibiotics only (control group).
Number of subjects: 350